Markets:

Overview

News

Currencies

International

Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.521 -0.069 (-4.35%)

Streaming Delayed Price Updated: 9:51 AM EDT, Jun 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NanoViricides, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats

March 20, 2023

By Ernest Dela Aglanu, Benzinga

Via TheNewswire.com

Topics Death Economy

With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It

March 08, 2023

With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It

Via News Direct

Topics Death

With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It

March 08, 2023

By Ernest Dela Aglanu, Benzinga

Via TheNewswire.com

Topics Death

With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It, And To Prepare For Battling Against The Next Likely Coronavirus Pandemic ↗

March 08, 2023

Read the latest report on NanoViricides, Inc (NYSE: NNVC) here.

Via Benzinga

uniQure To Rally Around 162%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

February 28, 2023

UBS cut the price target for Honeywell International Inc. (NASDAQ: HON) from $193 to $185. UBS analyst Chris Snyder maintained a Sell rating. Honeywell shares fell 0.2% to $191.99 in pre-market...

Via Benzinga

This Company Is Looking For A Monkeypox Drug As City Investigates Deaths

October 27, 2022

Learn more about NanoViricides, Inc. by gaining access to the latest research report

Via TheNewswire.com

Topics Death

NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly

September 19, 2022

Learn More about NanoViricides, Inc. by gaining access to the latest research report

Via TheNewswire.com

NanoViricides Has Filed its Quarterly Report - Company has Begun Production of Coronavirus Drug for Clinical Trials

February 15, 2023

Via ACCESSWIRE

NanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PT

January 04, 2023

Via ACCESSWIRE

NanoViricides, Inc. to Present at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ET

December 05, 2022

Via ACCESSWIRE

Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

November 15, 2022

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END

Via FinancialNewsMedia

Short Volatility Alert: NanoViricides, Inc. ↗

August 05, 2022

On Thursday, shares of NanoViricides, Inc. (NYSE: NNVC) experienced volatile short activity. After the activity, the stock price went up +48.37% to $3.65. The overall sentiment for NNVC has been...

Via Benzinga

NanoViricides, Inc. Has Filed its Quarterly Report: Coronavirus Drug NV-CoV-2 IND Stage

November 15, 2022

Via ACCESSWIRE

7 Speculative Penny Stocks Under $3 That Deserve Your Attention in Nov. ↗

October 28, 2022

While penny stocks are highly speculative and risky, you may still want to consider these seven opportunities.

Via InvestorPlace

This Company Is Looking For A Monkeypox Drug As City Investigates Deaths

October 27, 2022

By David Willey, Benzinga

Via News Direct

Topics Death

This Company Is Looking For A Monkeypox Drug As City Investigates Deaths ↗

October 27, 2022

New York City is investigating the cause of death for two people who died after contracting monkeypox.

Via Benzinga

NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug NV-CoV-2 IND Stage

October 14, 2022

Via ACCESSWIRE

NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly

September 19, 2022

By Rachael Green, Benzinga

Via News Direct

Monkeypox Is Popping Up In Places It Shouldn't But NanoViricides Says It May Have A Solution ↗

August 10, 2022

More than 30,000 confirmed or suspected cases of monkeypox have been reported across 93 countries in the world. While those numbers are still small scientists are now concerned that this sudden and...

Via Benzinga

NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy

August 09, 2022

Via ACCESSWIRE

NanoViricides Initiates New Drug Development To Combat Monkeypox Virus ↗

August 05, 2022

NanoViricides, Inc. (NYSE American: NNVC) reports that it has begun drug development to combat the monkeypox virus.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

August 04, 2022

Good morning! It's time for another dive into the biggest pre-market stock movers as we see what's affecting shares on Thursday!

Via InvestorPlace

Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday ↗

August 05, 2022

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share...

Via Benzinga

Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session ↗

August 04, 2022

Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday.

Via Benzinga

NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus

August 04, 2022

Via ACCESSWIRE

NanoViricides Patents Its Antiviral Nanotechnology for COVID-19, Continuing Its Development of Potentially Broad-Spectrum Drugs That Are Expected To Be Effective Even Against Emerging Variants ↗

May 25, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

58 Biggest Movers From Yesterday ↗

May 24, 2022

Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) gained 234.2% to close at $1.27 after the company announced it sold its complement portfolio for $60 million.

Via Benzinga

30 Stocks Moving In Monday's Mid-Day Session ↗

May 23, 2022

Gainers Evolve Transition Infrastructure LP (NYSE: SNMP) shares rose 29.2% to $0.6699 after jumping around 14% on Friday.

Via Benzinga

Mid-Morning Market Update: Markets Mixed; Broadcom In Talks To Buy VMWare ↗

May 23, 2022

U.S. stocks traded mixed this morning, with the Dow Jones gaining around 250 points on Monday.

Via Benzinga

24 Stocks Moving in Monday's Pre-Market Session ↗

May 23, 2022

Gainers Genocea Biosciences, Inc. (NASDAQ: GNCA) shares rose 33.8% to $0.2795 in pre-market trading after declining around 5% on Friday.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.